185 related articles for article (PubMed ID: 26087292)
21. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
Bondanelli M; Bonadonna S; Ambrosio MR; Doga M; Gola M; Onofri A; Zatelli MC; Giustina A; degli Uberti EC
Metabolism; 2005 Sep; 54(9):1174-80. PubMed ID: 16125529
[TBL] [Abstract][Full Text] [Related]
22. Contribution of gluconeogenesis and glycogenolysis to hepatic glucose production in acromegaly before and after pituitary microsurgery.
Höybye C; Chandramouli V; Efendic S; Hulting AL; Landau BR; Schumann WC; Wajngot A
Horm Metab Res; 2008 Jul; 40(7):498-501. PubMed ID: 18393170
[TBL] [Abstract][Full Text] [Related]
23. Could calgranulins and advanced glycated end products potentiate acromegaly pathophysiology?
Kruse CPS; Cottrill DA; Kopchick JJ
Growth Horm IGF Res; 2019; 46-47():1-4. PubMed ID: 31071497
[TBL] [Abstract][Full Text] [Related]
24. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
[TBL] [Abstract][Full Text] [Related]
25. Association between acromegaly and a single nucleotide polymorphism (rs2854744) in the IGFBP3 gene.
Gao M; Zhu B; Xu Z; Liu S; Liu J; Zhang G; Gao Y; Fan Y; Kang X
BMC Med Genet; 2018 Oct; 19(1):182. PubMed ID: 30290787
[TBL] [Abstract][Full Text] [Related]
26. Acromegaly in a family without a mutation in the menin gene.
Ackermann F; Krohn K; Windgassen M; Buchfelder M; Fahlbusch R; Paschke R
Exp Clin Endocrinol Diabetes; 1999; 107(1):93-6. PubMed ID: 10077364
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
[TBL] [Abstract][Full Text] [Related]
28. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
29. Role of IGF1-(CA)19 promoter microsatellite in the clinical presentation of acromegaly.
Sala E; Filopanti M; Ferrante E; Barbieri AM; Malchiodi E; Verrua E; Giavoli C; Lania AG; Arosio M; Beck-Peccoz P; Spada A; Mantovani G
Eur J Clin Invest; 2014 Dec; 44(12):1222-9. PubMed ID: 25370837
[TBL] [Abstract][Full Text] [Related]
30. Does IGF-1 play a role in the etiopathogenesis of non-functioning adrenocortical adenoma?
Bahadir CT; Ecemis GC; Atmaca H
J Endocrinol Invest; 2018 Nov; 41(11):1317-1323. PubMed ID: 29542030
[TBL] [Abstract][Full Text] [Related]
31. Suppressor of cytokine signaling-2 deficiency induces molecular and metabolic changes that partially overlap with growth hormone-dependent effects.
Rico-Bautista E; Greenhalgh CJ; Tollet-Egnell P; Hilton DJ; Alexander WS; Norstedt G; Flores-Morales A
Mol Endocrinol; 2005 Mar; 19(3):781-93. PubMed ID: 15563548
[TBL] [Abstract][Full Text] [Related]
32. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
[TBL] [Abstract][Full Text] [Related]
34. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly.
Puder JJ; Nilavar S; Post KD; Freda PU
J Clin Endocrinol Metab; 2005 Apr; 90(4):1972-8. PubMed ID: 15634715
[TBL] [Abstract][Full Text] [Related]
35. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess.
Wiesli P; Zwimpfer C; Zapf J; Schmid C
Acta Obstet Gynecol Scand; 2006; 85(8):900-5. PubMed ID: 16862465
[TBL] [Abstract][Full Text] [Related]
36. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly.
Grinspoon S; Clemmons D; Swearingen B; Klibanski A
J Clin Endocrinol Metab; 1995 Mar; 80(3):927-32. PubMed ID: 7533774
[TBL] [Abstract][Full Text] [Related]
37. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies.
Moore JS; Monson JP; Kaltsas G; Putignano P; Wood PJ; Sheppard MC; Besser GM; Taylor NF; Stewart PM
J Clin Endocrinol Metab; 1999 Nov; 84(11):4172-7. PubMed ID: 10566668
[TBL] [Abstract][Full Text] [Related]
38. Effects of acromegaly treatment and growth hormone on adipose tissue lipoprotein lipase.
Simsolo RB; Ezzat S; Ong JM; Saghizadeh M; Kern PA
J Clin Endocrinol Metab; 1995 Nov; 80(11):3233-8. PubMed ID: 7593431
[TBL] [Abstract][Full Text] [Related]
39. The Impact of Adipose Tissue on Insulin Resistance in Acromegaly.
Olarescu NC; Bollerslev J
Trends Endocrinol Metab; 2016 Apr; 27(4):226-237. PubMed ID: 26948712
[TBL] [Abstract][Full Text] [Related]
40. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
